2017. ISPOR Latin America Conference – Secukinumab shows greater symptomatic improvement versus infliximab in psoriatic arthritis: Comparative effectiveness up to 1 year assessed by matching-adjusted indirect comparisons

Strand V, McInnes I, Thom H, Hunger M, Lopes N, Gandhi K, et al. Secukinumab shows greater symptomatic improvement versus infliximab in psoriatic arthritis: Comparative effectiveness up to 1 year assessed by matching-adjusted indirect comparisons. Value Health. 2017 Oct-Nov;20(9):A935-A936. Presented at: ISPOR 6th Latin America Conference 2017; September 15-17, 2017; Sao Paulo, Brazil.